Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis)

Bibliography

• LIPSKY PE, ISAKSON PC: Outcome of specific COX-2 inhibition in rheumatoid arthritis. J. Rheumatol (1997) 24\(Suppl. 49):9–14.
   Google Scholar
• SIMON LS, LANZA FL, LIPSKY PE et al.: Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. (1998) 41(9):1591–1602.
   PubMed Web of Science ®Google Scholar
• CHAN CC, BOYCE S, BRIDEAU C et al: Rofecoxib [Vioxx, MK-0966; 4-(4(C-methylsulfonylpheny0-3-phenyl-2-(5H)-furanonel: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.' Pharmacol Exp. The]: (1999) 290(2):551–560.
   PubMed Web of Science ®Google Scholar
• SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284(10):1247–1255.
   Google Scholar
• GOLDSTEIN JL, SILVERSTEIN FE, AGRAWAL NM et al.: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am. J. Castroenterol (2000) 95(7):1681–1690.
   PubMed Web of Science ®Google Scholar
• CANNON GW, CALDWELL JR, HOLT P et al.: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum. (2000) 43(5):978–987.
   Google Scholar
• DAY R, MORRISON B, LUZA A et al.: A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch. Intern. Med. (2000) 160(12):1781–1787.
   PubMed Web of Science ®Google Scholar
• HAWKEY C, LAINE L, SIMON T et al: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum. (2000) 43(2):370–377.
   PubMed Web of Science ®Google Scholar
• ROSE ES, FERRANDIZ M, KISS Metal.: Steady-state plasma concentrations of rofecoxib in children (ages 2–5 years) with Juvenile Rheumatoid Arthritis (IRA). Arthritis Rheum. (2001) 44\(Suppl. 9):5291.
   Google Scholar
• CUMMINS R, WAGNER-WEINER L, PALLER A: Pseudoporphyria induced by celecoxib in a patient with juvenile rheumatoid arthritis. J. Rheumatol (2000) 27(12):2938–2940.
   PubMed Web of Science ®Google Scholar
• PERAZELLA MA, ERAS J: Are selective COX-2 inhibitors nephrotoxic? Am. Kidney Dis. (2000) 35(5):937–940.
   PubMed Web of Science ®Google Scholar
• WOLF G, PORTH J, STAHL RA: Acute renal failure associated with rofecoxib. Ann. Intern. Med. (2000) 133(5):394.
   PubMed Web of Science ®Google Scholar
• PAGET SA: Treatment of rheumatoid arthritis. In: Primer on the Rheumatic Diseases. JH Klippel (Ed.), Arthritis Foundation, Atlanta, USA (1997):155–160.
   Google Scholar
• GIANNINID EH, BREWER EJ, KUZMINA N et al.: Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double blind, placebo-controlled trial. N Engl. I Med. (1992) 326:1043–1049.
   PubMed Web of Science ®Google Scholar
• SINGEN BH, GOLDBACH-MANSKY R: Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and non-rheumatoid disorders. Rheum. Dis. Clin. North Am. (1997) 23:811–840.
   PubMed Web of Science ®Google Scholar
• RAVOLLI A, VIOLAS, RAMENGHI B et al.: Radiological progression in patients with juvenile chronic arthritis treated with methotrexate." Pediatr. (1998) 133:262–265.
   Google Scholar
• WEISS AH, WALLACE CA, SHERRY DD: Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis." Pediatr. (1998) 133:266–268.
   PubMed Web of Science ®Google Scholar
• RUPERTO N, MURRAY K, GERLONI V et al.: A randomized trial of methotrexate (MTX) in medium versus higher doses in children with Juvenile Idiopathic Arthritis (JIA) who failed on standard dose. Arthritis Rheum. (2002) 45(9):440.
   Google Scholar
• DIMITROVA P, SKAPENKO A, HERRMANN ML et al: Restriction of the novo pyrimidine biosynthesis inhibits Thl cell activation and promotes Th2 cell differentiation. J. Immunol (2002) 169(6):3392–3399.
   PubMed Web of Science ®Google Scholar
• SHARP JT, STRAND V, LEUNG H et al.: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. (2000) 43:495–505.
   PubMed Web of Science ®Google Scholar
• STRAND V, COHEN S, SCHIFF et al: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med. (1999) 159:2542–2550.
   PubMed Web of Science ®Google Scholar
• EMERY P, BREEVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (2000) 39:655–665.
   PubMed Web of Science ®Google Scholar
• SILVERMAN E, SPIEGEL L, HAWKINS D et al: An initial evaluation of the efficacy and safety of leflunomide in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. (2001) 44\(Suppl. 9):S272.
   Google Scholar
• FERRARIS JR, TAMBUTTI MI, REDAL MA: Conversion from azathioprin to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation (2000) 70:297–301.
   PubMed Web of Science ®Google Scholar
• CHAN TM, LIFK, TANG CS et al: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl. I Med. (2000) 343:1156–1162.
   PubMed Web of Science ®Google Scholar
• SCHWARTZMAN S, FLYNN T: Mycophenolate mofetil: A new treatment for refractory uveitis. Arthritis Rheum. (1999) 42(Suppl.):S1527.
   Google Scholar
• SPENCER CH, HICKEY K: The short term safety and efficacy of mycophenolate (Cellcept) in treatment of children with pediatric rheumatic diseases. Arthritis Rheum. (1999) 42 (Suppl.): S184.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl. I Med. (1997) 337(3):141–147.
   PubMed Web of Science ®Google Scholar
• ••Most important description of antiTNF efficacy/safety in adult RA over a 3-month period.
   Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340(4):253–259.
   PubMed Web of Science ®Google Scholar
• LOVELL DJ, GIANNINI EH, WHITMORE JB, SOFFES L, FINCK BK: Safety and efficacy of tumor necrosis factor receptor P75 FC fusion protein (TNFR:FC;ENBREIM in polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. (1998) 41 (Suppl.):S130.
   Google Scholar
• ••First successful description of a biologicalagent for JIA.
   Google Scholar
• LOVELL DJ, GIANNINI EH, LANGE M et al.: Safety and efficacy of enbrel (etanercept) in the extended treatment of polyarticular IRA. Arthritis Rheum. (1999) 42(Suppl.):S117.
   Google Scholar
• KIETZ DA, PEPMUELLER PH, MOORE TL et al: Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. Rheumatol (2001) 28(2):360–362.
   Web of Science ®Google Scholar
• LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl. I Med. (2000) 342(11):763–769.
   PubMed Web of Science ®Google Scholar
• •This article is the first collaborative study that evaluates safety and efficacy of etanercept in polyarticular onset JIA.
   Google Scholar
• KIETZ DA, PEPMUELLER PH, MOORE TL et al.: Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann. Rheum. Dis. (2002) 61(2):171–173.
   PubMed Web of Science ®Google Scholar
• TAKEI S, GROH D, BERNSTEIN B, SHAHAM B, GALLAGHER K, REIFF A: Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. Rheumatol (2001) 28(7):1677–1680.
   Web of Science ®Google Scholar
• KIMURA Y, LI S, EBNER-LYON L, IMUNDO L: Treatment of systemic JIA with etanercept: results of a survey. Arthritis Rheum. (2000) 43(Suppl.):S257.
   Google Scholar
• ROTHMAN D, SMITH K, KIMURA S: Safety and efficacy of etanercept (enbrel) in children with IRA less than 4 years of age. Arthritis Rheum. (2001) 44(Suppl.):S292.
   Google Scholar
• TEN CATE R, VAN SUIJLEKOM-SMIT LW, BRINKMAN DM, BEKKERING WP, JANSEN-VAN WIJNGAARDEN CJ, VOSSEN JM: Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology (Oxford) (2002) 41(2):228–229.
   PubMed Web of Science ®Google Scholar
• HIGGINS GC, JONES K, RENNEBOHM RM: Variable response of Systemic Juvenile Rheumatoid Arthritis to etanercept. Arthritis Rheum. (2000) 43(Suppl.):S257.
   Google Scholar
• LIPSKY P, CLAIR WS, FURST D et al: 54-week clinical and radiographic results from the ATTRACT trial: a Phase III study of infliximab (remicade) in patients with active RA despite methotrexate. Arthritis Rheum. (1999) 42(Suppl.):S401.
   Google Scholar
• HANAUER SB, SCHAIBLE TF, DEWOODY KL et al.: Long-term follow-up of patients treated with infliximab (anti-TNF alpha antibody) in clinical trials. Gastroenterology (2000) 118\(Suppl. 2):4.
   Google Scholar
• PISETSKY DS: Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum. (2000) 43(11):2381–2382.
   PubMed Web of Science ®Google Scholar
• CHARLES PJ, SMEENK RJ, DE JONG J, FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. (2000) 43(11):2383–2390.
   PubMed Web of Science ®Google Scholar
• ••This article investigates the induction ofsecondary autoantibodies in RA patients treated with infliximab.
   Google Scholar
• GERLONI V, PONTIKAKI I, DESIATI Fet al.: Infliximab in the treatment of persistently active refractory juvenile idiopathic (chronic) arthritis: a short-term pilot study. Arthritis Rheum. (2000) 43(Suppl.):S256.
   Google Scholar
• LAHDENNE P, HONKANEN V: Infliximab versus etanercept in the treatment of severe juvenile chronic arthritis. Arthritis Rheum. (2000) 43(Suppl.):S381.
   Google Scholar
• KIMURA Y, IMUNDO LF, LI SC: High dose infliximab in the treatment of resistant systemic juvenile rheumatoid arthritis. Arthritis Rheum. (2001) 44\(Suppl. 9):S272.
   Google Scholar
• ELLIOTT MJ, WOO P, CHARLES P, LONG-FOX A, WOODY IN, MAINI RN: Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br. J. Rheumatol (1997) 36(5):589–593.
   PubMedGoogle Scholar
• •First report of high-dose use of infliximab in one case of SoJIA with clinical improvement.
   Google Scholar
• WEISMAN M, KEYSTONE E, PAULUS H et al.: A dose escalation study designed to demonstrate the safety, tolerability and efficacy of the fully human anti-TNF antibody, D2E7, given in combination with methotrexate (MTX) in patients with active RA. Arthritis Rheum. (2000) 43(Suppl.):S391.
   Google Scholar
• SCHMELING H, MATHONY K, JOHN V, KEYSSER G, BURDACH S, HORNEFF G: A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann. Rheum. Dis. (2001) 60(4):410–412.
   PubMed Web of Science ®Google Scholar
• JIANG Y, GENANT HK, WATT I et al: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. (2000) 43(5):1001–1009.
   PubMed Web of Science ®Google Scholar
• BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41(12):2196–2204.
   PubMed Web of Science ®Google Scholar
• NUKI G, BRESHNIHAN B, WOOLLEY JM: Functional status improvement in subjects with rheumatoid arthritis receiving anakinra. Arthritis Rheum. (2001) 44(Suppl.):S372.
   Google Scholar
• FLEISCHMAN R, TESSER J, SCHECHTMAN J et al.: A safety trial of anakinra: recombinant interleukin-1 receptor antagonist (IL-1RA), in a large, placebo controlled heterogeneous population of patients with rheumatoid arthritis. Arthritis Rheum. (2001) 44(Suppl.):S84.
   Google Scholar
• BRESNIHAN B, CHAN WW, WOOLLEY JM: Increases in productivity after six months of anakinra treatment in patients with rheumatoid arthritis. Arthritis Rheum. (2001) 44(Suppl.):S77.
   Google Scholar
• COHEN S, NAKELSKY S, MULANI P et al.: The impact of anakinra therapy on patient-centered outcomes in rheumatoid arthritis. Arthritis Rheum. (2001) 44(Suppl.):S77.
   Google Scholar
• COHEN S, HURD E, CUSH J et aL: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum. (2002) 46(3):614–24.
   PubMed Web of Science ®Google Scholar
• SCHIFF MH, BULPITT K, WEAVER AA et al.: Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis. Arthritis Rheum. (2001) 44(Suppl.):S79.
   Google Scholar
• MARTIN SW, NGUYEN L, STOUCH BJ et al: Pharmacokinetics (PK) of neither anakinra (interleukin-1 receptor antagonist, IL-lra) nor pegylated soluble tumor necrosis factor receptorType I (PEG sTNF-RI) were altered after combination treatment in subjects with rheumatoid arthritis. Arthritis Rheum. (2001) 44(Suppl.):S79.
   Google Scholar
• ANDRIAS R, PORRAS 0, RUDGE S et al.: Preliminary data from a study of Kinerettm (anakinra) in children with Juvenile Rheumatoid Arthritis. Arthritis Rheum. (2002) 45(9):496.
   Google Scholar
• ST CLAIR EW: Interleuldn 10 treatment for rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58\(Suppl. 1):199–1102.
   Google Scholar
• •Interesting review about IL-10 and its clinical applications in RA.
   Google Scholar
• MAINI RN, PAULUS H, BREEDVELD FC et al: rHuIL-10 in subjects with active rheumatoid arthritis (RA): a Phase I and cytokine response study. Arthritis Rheum. (1997) 40(Suppl.):S170.
   Google Scholar
• WEINBLATT ME, ST CLAIR EW, BREEDVELD FC et al: rHuIL-10 (Tenovil) plus methotrexate (MTX) in active rheumatoid arthritis (RA): a Phase I/ II study. Arthritis Rheum. (1999) 42(Suppl.):S224.
   Google Scholar
• CHOY EH, ISENBERG DA, FARROW S et al.: A double-blind, randomized, placebo-controlled trial of anti-interleukin-6 (IL-6) receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. (2001) 44(Suppl.):S274.
   Google Scholar
• DE BENEDETTI F, MASSA M, PIGNATTI P, ALBANI S, NOVICK D, MARTINI A: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. (1994) 93(5):2114–2119.
   PubMed Web of Science ®Google Scholar
• DE BENEDETTI F, ROBBIONI P, MASSA M, VIOLA S, ALBANI S, MARTINI A: Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin. Exp. Rheumatol (1992) 10(5):493–498.
   PubMed Web of Science ®Google Scholar
• DE BENEDETTI F, MASSA M, ROBBIONI P, RAVELLI A, BURGIO GR, MARTINI A: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. (1991) 34(9):1158–1163.
   PubMed Web of Science ®Google Scholar
• BROZIK M, ROSZTOCZY I, MERETEY K et al: Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production.' Rheumatol (1992) 19M:563–568.
   Google Scholar
• YOKOTA S, MIYAMAE T, IMAGAWA T et al.: Therapeutic efficacy of humanized anti-IL-6-receptor antibody in systemic juvenile idiopathic arthritis. Arthritis Rheum. (2001) 44 (Suppl.) :S291.
   Google Scholar
• ARNASON BG, DAYAL A, QU ZX et al.:Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin. Immunopathol (1996) 18:125–148.
   PubMed Web of Science ®Google Scholar
• REP MH, HINTZEN RQ, POLMAN CH, VAN LIER RA: Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. Neuraimmuna (1996) 67:111–118.
   PubMed Web of Science ®Google Scholar
• SUNDEL RP, WALLACE CA, ZURAKOWSKI D: Pilot trial of interferon (Avonex) in JRA. Arthritis Rheum. (2001) 44(Suppl.):S272.
   Google Scholar
• COTO C, VARELA G, HERNANDEZ V, DEL ROSARIO M, LOPEZ-SAURA P: Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis. Biotherapy (1998) 11(1):15–20.
   PubMedGoogle Scholar
• WULFFRAAT N, VAN ROYEN A, BIERINGS M, VOSSEN J, KUIS W: Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet (1999) 353:550–553.
   PubMed Web of Science ®Google Scholar
• •This article is the first to report successful use of AHSCT in children with longstanding and severe polyarticular onset and systemic JIA.
   Google Scholar
• WULFFRAAT NM, BRINKMAN D, PRIEUR A et al.: Autologous stem-cell transplantation for refractory juvenile idiopathic arthritis. Arthritis Rheum. (2000) 43(Suppl.):S381.
   Google Scholar
• KLEER I, BRINKMAN D, TEN CATE R et al.: 18 children after autologous stem cell transplantation for refractory juvenile idiopathic arthritis: 1 to 51 months of follow-up. Arthritis Rheum. (2001) 44(Suppl.):S273.
   Google Scholar
• WULFFRAAT NM, KUIS W: Treatment ofrefractory juvenile idiopathic arthritis. Rheumatol (2001) 28(5):929–931.
   Web of Science ®Google Scholar
• MANGGE H, SCHAUENSTEIN K: Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine (1998) 1O(6):471–480.
   Web of Science ®Google Scholar
• DE BENEDETTI F, PIGNATTI P, BERNASCONI S et al.: Interleuldn 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes. Rheumatol (1999) 26(2):425–431.
   Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. j Immunot (1999) 163(1):380–386.
   Google Scholar
• LEHMAN TJ, STRIEGEL KH, ONEL KB: Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. Pediatr. (2002) 140(1):125–127.
   Web of Science ®Google Scholar
• •Article reporting the safety and efficacy of thalidomide in SOU in a short-term follow up.
   Google Scholar
• WEBB LM, WALMSLEY MJ, FELDMANN M: Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur.j Immunot (1996) 26(10):2320–2328.
   PubMed Web of Science ®Google Scholar
• NAGLER-ANDERSON C, BOBER LA, ROBINSON ME, SISKIND GW, THORBECKE GJ: Suppression of Type II collagen-induced arthritis by intragastric administration of soluble Type II collagen. Proc. Natl. Acad. Sci. USA (1986) 83(19):7443–7446.
   PubMed Web of Science ®Google Scholar
• TRENTHAM DE, DYNESIUS-TRENTHAM RA, ORAV E et al.: Effects of oral administration of Type II collagen on rheumatoid arthritis. Science (1993) 261:1727–1730.
   PubMed Web of Science ®Google Scholar
• MCKOWN KM, CARBONE LD, KAPLAN SB et al.: Lack of efficacy of oral bovine Type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. (1999) 42(6):1204–1208.
   PubMed Web of Science ®Google Scholar